{
  "drug_name": "Amiodarone",
  "url": "https://wikem.org/wiki/Amiodarone",
  "scraped_at": "2026-01-10T02:56:28.542422",
  "sections": {
    "General": {
      "text": "Type:\nAntiarrhythmics\nDosage Forms: injectable solution, tablet\nRoutes of Administration: IV, PO\nCommon Trade Names: Cordarone, Pacerone, Nexterone",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Antiarrhythmics",
          "url": "https://wikem.org/wiki/Antiarrhythmics"
        }
      ]
    },
    "Adult_Dosing": {
      "text": "",
      "subsections": {
        "V-fib/pulseless_V-tach": {
          "text": "Loading dose = 300mg IV bolus followed by 150mg bolus PRN",
          "tables": []
        },
        "Stable_wide_complex_tachycardia_(e.g._V-tach)_or_SVT": {
          "text": "150 mg in 100mL D5W over 10min (15 mg/min), followed by 1 mg/min drip over 6hrs (360 mg total)\n[1]\nThen 0.5 mg/min drip over next 18 hrs (540 mg total)\nOral dosage after IV infusion is 400 -800 mg PO daily",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "Pregnancy Rating\n: D\nLactation Risk Categories\n: Unsafe\nRenal Dosing- no adjustment\nAdult\nPediatric\nHepatic Dosing- caution and consider dose decrease\nAdult\nPediatric",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Pregnancy Rating",
          "url": "https://wikem.org/wiki/Drug_Ratings_in_Pregnancy"
        },
        {
          "text": "Lactation Risk Categories",
          "url": "https://wikem.org/wiki/Lactation_Risk_Categories"
        }
      ]
    },
    "Contraindications": {
      "text": "Allergy to class/drug\nIodine or shellfish allergy\nPregnancy",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Amiodarone_Adverse_Effects": {
          "text": "Bradycardia\nHypotension with older solvent-based formulation. Uncommon with newer aqueous formulation.\nProlonged QT\nThyrotoxicosis\n[2]\nBetween 5-20% of patients treated with amiodarone have thyrotoxicosis (higher in areas of iodine deficiency)\nIodine-induced hyperthyroidism\nIt is thought that the iodine load may unmask hyperthyroidism in patients with multinodular goiter and subclinical Gravesâ€™ disease\nDrug-induced destructive thyroiditis\nMore commonly, the cytotoxic effects of amiodarone destroy thyroid cells, resulting in a release of preformed hormone.\nAmiodarone pulmonary toxicity\nHyperpigmentation rash",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Bradycardia",
          "url": "https://wikem.org/wiki/Bradycardia"
        },
        {
          "text": "Prolonged QT",
          "url": "https://wikem.org/wiki/Prolonged_QT"
        },
        {
          "text": "Thyrotoxicosis",
          "url": "https://wikem.org/wiki/Thyrotoxicosis"
        },
        {
          "text": "Amiodarone pulmonary toxicity",
          "url": "https://wikem.org/wiki/Amiodarone_pulmonary_toxicity"
        }
      ]
    },
    "Pharmacology": {
      "text": "Half-life: 58 days\nMetabolism: Liver extensively\nExcretion: Bile primarily",
      "subsections": {
        "Mechanism_of_Action": {
          "text": "Class III - Inhibits potassium channels\nImpairs SA and AV node conduction\nDecreases automaticity\nProlongs refractory period in accessory pathways\nAlso has class I & II properties",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    }
  }
}